Download PDF
Semin Neurol 2010; 30(2): 154-166
DOI: 10.1055/s-0030-1249224
© Thieme Medical Publishers

Diagnosis and Management of Chronic Daily Headache

Ivan Garza1 , Todd J. Schwedt2
  • 1Department of Neurology, Mayo Clinic, Rochester, Minnesota
  • 2Washington University Headache Center, Washington University School of Medicine, St. Louis, Missouri
Further Information

Publication History

Publication Date:
29 March 2010 (online)

   Permissions and Reprints

ABSTRACT

Chronic daily headache (CDH) is a descriptive term that encompasses multiple headache diagnoses and affects ~4% of the general adult population. Chronic daily headache results in significant pain and suffering with substantial impact on quality of life, and enormous economic costs to society. Although most patients with primary CDH suffer from chronic migraine or chronic tension-type headache, other primary and secondary headache disorders can also manifest as a CDH syndrome. For CDH management to succeed, secondary headaches need to be ruled out with proper investigations when judged necessary. If the diagnosis of primary CDH is established, diagnosis of the specific CDH subtype is imperative to institute appropriate treatment. The diagnosis and management of distinct CDH entities, chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua, are the primary forms of CDH and the emphasis of this review. Although, strictly speaking, medication overuse headache is a secondary form of CDH, it is also highlighted in this review given its frequent association with primary CDH.

KEYWORDS

Chronic - daily - headache - migraine - hemicrania

REFERENCES

  • 1 Scher A I, Stewart W F, Liberman J, Lipton R B. Prevalence of frequent headache in a population sample.  Headache. 1998;  38(7) 497-506
    CrossrefPubMedGoogle Scholar
  • 2 Lu S R, Fuh J L, Chen W T, Juang K D, Wang S J. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors.  Cephalalgia. 2001;  21(10) 980-986
    CrossrefPubMedGoogle Scholar
  • 3 Wang S J, Fuh J L, Lu S R et al.. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up.  Neurology. 2000;  54(2) 314-319
    CrossrefPubMedGoogle Scholar
  • 4 Stewart W F, Ricci J A, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce.  JAMA. 2003;  290(18) 2443-2454
    CrossrefPubMedGoogle Scholar
  • 5 Lipton R B, Stewart W F, Scher A I. Epidemiology and economic impact of migraine.  Curr Med Res Opin. 2001;  17(Suppl 1) s4-s12
    CrossrefPubMedGoogle Scholar
  • 6 Scher A I, Midgette L A, Lipton R B. Risk factors for headache chronification.  Headache. 2008;  48(1) 16-25
    CrossrefPubMedGoogle Scholar
  • 7 Scher A I, Stewart W F, Buse D, Krantz D S, Lipton R B. Major life changes before and after the onset of chronic daily headache: a population-based study.  Cephalalgia. 2008;  28(8) 868-876
    CrossrefPubMedGoogle Scholar
  • 8 Scher A I, Stewart W F, Lipton R B. Caffeine as a risk factor for chronic daily headache: a population-based study.  Neurology. 2004;  63(11) 2022-2027
    PubMedGoogle Scholar
  • 9 Scher A I, Stewart W F, Ricci J A, Lipton R B. Factors associated with the onset and remission of chronic daily headache in a population-based study.  Pain. 2003;  106(1-2) 81-89
    CrossrefPubMedGoogle Scholar
  • 10 Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population.  Headache. 1999;  39(3) 190-196
    CrossrefPubMedGoogle Scholar
  • 11 Guitera V, Muñoz P, Castillo J, Pascual J. Quality of life in chronic daily headache: a study in a general population.  Neurology. 2002;  58(7) 1062-1065
    PubMedGoogle Scholar
  • 12 D'Amico D, Usai S, Grazzi L et al.. Quality of life and disability in primary chronic daily headaches.  Neurol Sci. 2003;  24(Suppl 2) S97-S100
    CrossrefPubMedGoogle Scholar
  • 13 Harwood R H, Sayer A A, Hirschfeld M. Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios.  Bull World Health Organ. 2004;  82(4) 251-258
    PubMedGoogle Scholar
  • 14 Munakata J, Hazard E, Serrano D et al.. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.  Headache. 2009;  49(4) 498-508
    CrossrefPubMedGoogle Scholar
  • 15 Katsarava Z, Schneeweiss S, Kurth T et al.. Incidence and predictors for chronicity of headache in patients with episodic migraine.  Neurology. 2004;  62(5) 788-790
    CrossrefPubMedGoogle Scholar
  • 15a Lipton R B. Tracing transformation: chronic migration classification, progression, and epidemiology.  Neurology. 2009;  72(5 Suppl) S3-S7
    CrossrefPubMedGoogle Scholar
  • 16 Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients.  Neurology. 2001;  57(1) 132-134
    PubMedGoogle Scholar
  • 17 Schwedt T J, Dodick D W. Advanced neuroimaging of migraine.  Lancet Neurol. 2009;  8(6) 560-568
    CrossrefPubMedGoogle Scholar
  • 18 Welch K M, Nagesh V, Aurora S K, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?.  Headache. 2001;  41(7) 629-637
    CrossrefPubMedGoogle Scholar
  • 19 Kruit M C, Launer L J, Overbosch J, van Buchem M A, Ferrari M D. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study.  Cephalalgia. 2009;  29(3) 351-359
    CrossrefPubMedGoogle Scholar
  • 20 Schmitz N, Admiraal-Behloul F, Arkink E B et al.. Attack frequency and disease duration as indicators for brain damage in migraine.  Headache. 2008;  48(7) 1044-1055
    CrossrefPubMedGoogle Scholar
  • 21 Valfrè W, Rainero I, Bergui M, Pinessi L. Voxel-based morphometry reveals gray matter abnormalities in migraine.  Headache. 2008;  48(1) 109-117
    CrossrefPubMedGoogle Scholar
  • 22 Rocca M A, Ceccarelli A, Falini A et al.. Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study.  Stroke. 2006;  37(7) 1765-1770
    CrossrefPubMedGoogle Scholar
  • 23 Schmitz N, Arkink E B, Mulder M et al.. Frontal lobe structure and executive function in migraine patients.  Neurosci Lett. 2008;  440(2) 92-96
    CrossrefPubMedGoogle Scholar
  • 24 Granziera C, DaSilva A F, Snyder J, Tuch D S, Hadjikhani N. Anatomical alterations of the visual motion processing network in migraine with and without aura.  PLoS Med. 2006;  3(10) e402
    CrossrefPubMedGoogle Scholar
  • 25 Ashkenazi A, Mushtaq A, Yang I, Oshinsky M L. Ictal and interictal phonophobia in migraine-a quantitative controlled study.  Cephalalgia. 2009;  29(10) 1042-1048
    CrossrefPubMedGoogle Scholar
  • 26 Olesen J, Bousser M G, Diener H C Headache Classification Committee et al. New appendix criteria open for a broader concept of chronic migraine.  Cephalalgia. 2006;  26(6) 742-746
    CrossrefPubMedGoogle Scholar
  • 27 Silberstein S D, Lipton R B, Dodick D W Topiramate Chronic Migraine Study Group et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.  Headache. 2007;  47(2) 170-180
    CrossrefPubMedGoogle Scholar
  • 28 Diener H C, Bussone G, Van Oene J C, Lahaye M, Schwalen S, Goadsby P J. TOPMAT-MIG-201(TOP-CHROME) Study Group . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.  Cephalalgia. 2007;  27(7) 814-823
    CrossrefPubMedGoogle Scholar
  • 29 Spira P J, Beran R G. Australian Gabapentin Chronic Daily Headache Group . Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study.  Neurology. 2003;  61(12) 1753-1759
    PubMedGoogle Scholar
  • 30 Saper J R, Lake III A E, Cantrell D T, Winner P K, White J R. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.  Headache. 2002;  42(6) 470-482
    CrossrefPubMedGoogle Scholar
  • 31 Saper J R, Silberstein S D, Lake III A E, Winters M E. Double-blind trial of fluoxetine: chronic daily headache and migraine.  Headache. 1994;  34(9) 497-502
    CrossrefPubMedGoogle Scholar
  • 32 Krymchantowski A V, Silva M T, Barbosa J S, Alves L A. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study.  Headache. 2002;  42(6) 510-514
    CrossrefPubMedGoogle Scholar
  • 33 Rapoport A M, Sheftell F D, Tepper S J, Bigal M. Levetiracetam in the preventive treatment of transformed migraine.  Curr Ther Res. 2005;  66 212-221
    CrossrefPubMedGoogle Scholar
  • 34 Mathew N T, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study.  Headache. 1991;  31(2) 71-74
    CrossrefPubMedGoogle Scholar
  • 35 Freitag F G, Diamond S, Diamond M L, Urban G J. Divalproex in the long-term treatment of chronic daily headache.  Headache. 2001;  41(3) 271-278
    CrossrefPubMedGoogle Scholar
  • 36 Naumann M, So Y, Argoff C E Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology. 2008;  70(19) 1707-1714
    CrossrefPubMedGoogle Scholar
  • 37 Spengos K, Theleritis C, Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach?.  Headache. 2008;  48(2) 284-286
    CrossrefPubMedGoogle Scholar
  • 38 Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine.  Headache. 2008;  48(9) 1337-1342
    CrossrefPubMedGoogle Scholar
  • 39 Ciancarelli I, Tozzi-Ciancarelli M G, Spacca G, Di Massimo C, Carolei A. Relationship between biofeedback and oxidative stress in patients with chronic migraine.  Cephalalgia. 2007;  27(10) 1136-1141
    CrossrefPubMedGoogle Scholar
  • 40 Martin P R, Forsyth M R, Reece J. Cognitive-behavioral therapy versus temporal pulse amplitude biofeedback training for recurrent headache.  Behav Ther. 2007;  38(4) 350-363
    CrossrefPubMedGoogle Scholar
  • 41 Lockett D M, Campbell J F. The effects of aerobic exercise on migraine.  Headache. 1992;  32(1) 50-54
    CrossrefPubMedGoogle Scholar
  • 42 Marcus D A, Scharff L, Mercer S, Turk D C. Nonpharmacological treatment for migraine: incremental utility of physical therapy with relaxation and thermal biofeedback.  Cephalalgia. 1998;  18(5) 266-272, discussion 242
    CrossrefPubMedGoogle Scholar
  • 43 Seok J I, Cho H I, Chung C S. From transformed migraine to episodic migraine: reversion factors.  Headache. 2006;  46(7) 1186-1190
    CrossrefPubMedGoogle Scholar
  • 44 Schwartz B S, Stewart W F, Simon D, Lipton R B. Epidemiology of tension-type headache.  JAMA. 1998;  279(5) 381-383
    CrossrefPubMedGoogle Scholar
  • 45 Lavados P M, Tenhamm E. Epidemiology of tension-type headache in Santiago, Chile: a prevalence study.  Cephalalgia. 1998;  18(8) 552-558
    CrossrefPubMedGoogle Scholar
  • 46 Russell M B, Levi N, Saltyte-Benth J, Fenger K. Tension-type headache in adolescents and adults: a population based study of 33,764 twins.  Eur J Epidemiol. 2006;  21(2) 153-160
    CrossrefPubMedGoogle Scholar
  • 47 Bendtsen L, Jensen R. Tension-type headache: the most common, but also the most neglected, headache disorder.  Curr Opin Neurol. 2006;  19(3) 305-309
    PubMedGoogle Scholar
  • 48 Juang K D, Wang S J, Fuh J L, Lu S R, Su T P. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes.  Headache. 2000;  40(10) 818-823
    CrossrefPubMedGoogle Scholar
  • 49 Fumal A S. Chronic tension-type headache. In: Goadsby PJ, Dodick DW Chronic Daily Headache for Clinicians. 1st Ed. Hamilton, Ontario; BC Decker Inc 2005: 57-64
    Google Scholar
  • 50 Mathew N T. Tension-type headache.  Curr Neurol Neurosci Rep. 2006;  6(2) 100-105
    CrossrefPubMedGoogle Scholar
  • 51 Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache.  Arch Neurol. 1996;  53(4) 373-376
    PubMedGoogle Scholar
  • 52 Buchgreitz L, Egsgaard L L, Jensen R, Arendt-Nielsen L, Bendtsen L. Abnormal pain processing in chronic tension-type headache: a high-density EEG brain mapping study.  Brain. 2008;  131(Pt 12) 3232-3238
    CrossrefPubMedGoogle Scholar
  • 53 Pielsticker A, Haag G, Zaudig M, Lautenbacher S. Impairment of pain inhibition in chronic tension-type headache.  Pain. 2005;  118(1-2) 215-223
    CrossrefPubMedGoogle Scholar
  • 54 Schmidt-Wilcke T, Leinisch E, Straube A et al.. Gray matter decrease in patients with chronic tension type headache.  Neurology. 2005;  65(9) 1483-1486
    CrossrefPubMedGoogle Scholar
  • 55 Headache Classification Subcommittee of the International Headache Society . The International Classification of Headache Disorders, 2nd Edition.  Cephalalgia. 2004;  24(Suppl 1) 1-160
    PubMedGoogle Scholar
  • 56 Jensen R, Becker W J. Symptomatology of chronic tension-type headaches. In: Olesen J, Ramadan NM, Tfelt-Hansen P, Welch KMA The Headaches. 3rd ed. Philadelphia; Lippincott Williams and Wilkins 2006: 693-699
    Google Scholar
  • 57 Bigal M E, Lipton R B. Tension-type headache: classification and diagnosis.  Curr Pain Headache Rep. 2005;  9(6) 423-429
    CrossrefPubMedGoogle Scholar
  • 58 Lenaerts M E. Pharmacoprophylaxis of tension-type headache.  Curr Pain Headache Rep. 2005;  9(6) 442-447
    CrossrefPubMedGoogle Scholar
  • 59 Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.  J Neurol Neurosurg Psychiatry. 1996;  61(3) 285-290
    CrossrefPubMedGoogle Scholar
  • 60 Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache.  Neurology. 2004;  62(10) 1706-1711
    PubMedGoogle Scholar
  • 61 Garza I, Swanson J W. Prophylaxis of migraine.  Neuropsychiatr Dis Treat. 2006;  2(3) 281-291
    CrossrefPubMedGoogle Scholar
  • 62 Holroyd K A, O'Donnell F J, Stensland M, Lipchik G L, Cordingley G E, Carlson B W. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial.  JAMA. 2001;  285(17) 2208-2215
    CrossrefPubMedGoogle Scholar
  • 63 Cohen G L. Protriptyline, chronic tension-type headaches, and weight loss in women.  Headache. 1997;  37(7) 433-436
    CrossrefPubMedGoogle Scholar
  • 64 Lampl C, Marecek S, May A, Bendtsen L. A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache.  Cephalalgia. 2006;  26(10) 1203-1208
    CrossrefPubMedGoogle Scholar
  • 65 Yurekli V A, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu H R, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups.  J Headache Pain. 2008;  9(1) 37-41
    CrossrefPubMedGoogle Scholar
  • 66 Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study.  Headache. 1992;  32(10) 509-513
    CrossrefPubMedGoogle Scholar
  • 67 Murros K, Kataja M, Hedman C et al.. Modified-release formulation of tizanidine in chronic tension-type headache.  Headache. 2000;  40(8) 633-637
    CrossrefPubMedGoogle Scholar
  • 68 Langemark M, Olesen J. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial.  Headache. 1994;  34(1) 20-24
    CrossrefPubMedGoogle Scholar
  • 69 Holroyd K A, Labus J S, O'Donnell F J, Cordingley G E. Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation.  Headache. 2003;  43(9) 999-1004
    CrossrefPubMedGoogle Scholar
  • 70 Adelman L C, Adelman J U, Von Seggern R, Mannix L K. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting.  Headache. 2000;  40(7) 572-580
    CrossrefPubMedGoogle Scholar
  • 71 Mitsikostas D D, Gatzonis S, Thomas A, Ilias A. Buspirone vs amitriptyline in the treatment of chronic tension-type headache.  Acta Neurol Scand. 1997;  96(4) 247-251
    CrossrefPubMedGoogle Scholar
  • 72 Schulte-Mattler W J, Martinez-Castrillo J C. Botulinum toxin therapy of migraine and tension-type headache: comparing different botulinum toxin preparations.  Eur J Neurol. 2006;  13(Suppl 1) 51-54
    CrossrefPubMedGoogle Scholar
  • 73 Walker Z, Walker R W, Robertson M M, Stansfeld S. Antidepressant treatment of chronic tension-type headache: a comparison between fluoxetine and desipramine.  Headache. 1998;  38(7) 523-528
    CrossrefPubMedGoogle Scholar
  • 74 Söderberg E, Carlsson J, Stener-Victorin E. Chronic tension-type headache treated with acupuncture, physical training and relaxation training. Between-group differences.  Cephalalgia. 2006;  26(11) 1320-1329
    CrossrefPubMedGoogle Scholar
  • 75 Melis P M, Rooimans W, Spierings E L, Hoogduin C A. Treatment of chronic tension-type headache with hypnotherapy: a single-blind time controlled study.  Headache. 1991;  31(10) 686-689
    CrossrefPubMedGoogle Scholar
  • 76 Quinn C, Chandler C, Moraska A. Massage therapy and frequency of chronic tension headaches.  Am J Public Health. 2002;  92(10) 1657-1661
    CrossrefPubMedGoogle Scholar
  • 77 Bronfort G, Nilsson N, Haas M et al.. Non-invasive physical treatments for chronic/recurrent headache.  Cochrane Database Syst Rev. 2004;  (3) CD001878
    PubMedGoogle Scholar
  • 78 Bigal M E, Rapoport A M, Sheftell F D, Tepper S J, Lipton R B. Transformed migraine and medication overuse in a tertiary headache centre—clinical characteristics and treatment outcomes.  Cephalalgia. 2004;  24(6) 483-490
    CrossrefPubMedGoogle Scholar
  • 79 Mathew N T, Kurman R, Perez F. Drug induced refractory headache—clinical features and management.  Headache. 1990;  30(10) 634-638
    CrossrefPubMedGoogle Scholar
  • 80 Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications.  Headache. 2006;  46(Suppl 4) S202-S211
    CrossrefPubMedGoogle Scholar
  • 81 Kavuk I, Katsarava Z, Selekler M et al.. Clinical features and therapy of medication overuse headache.  Eur J Med Res. 2004;  9(12) 565-569
    PubMedGoogle Scholar
  • 82 Smith T R, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management.  Drugs. 2004;  64(22) 2503-2514
    CrossrefPubMedGoogle Scholar
  • 83 Bigal M E, Serrano D, Buse D, Scher A, Stewart W F, Lipton R B. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study.  Headache. 2008;  48(8) 1157-1168
    CrossrefPubMedGoogle Scholar
  • 84 Bigal M E, Lipton R B. Excessive acute migraine medication use and migraine progression.  Neurology. 2008;  71(22) 1821-1828
    CrossrefPubMedGoogle Scholar
  • 85 Diener H C, Limmroth V. Medication-overuse headache: a worldwide problem.  Lancet Neurol. 2004;  3(8) 475-483
    CrossrefPubMedGoogle Scholar
  • 86 Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headaches de novo?.  Headache. 1988;  28(1) 61-62
    CrossrefPubMedGoogle Scholar
  • 87 Ayzenberg I, Obermann M, Nyhuis P et al.. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures.  Cephalalgia. 2006;  26(9) 1106-1114
    CrossrefPubMedGoogle Scholar
  • 88 Fumal A, Laureys S, Di Clemente L et al.. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine.  Brain. 2006;  129(Pt 2) 543-550
    CrossrefPubMedGoogle Scholar
  • 89 Boes C J, Black D F, Dodick D W. Pathophysiology and management of transformed migraine and medication overuse headache.  Semin Neurol. 2006;  26(2) 232-241
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Saper J R, Hamel R L, Lake III A E. Medication overuse headache (MOH) is a biobehavioural disorder.  Cephalalgia. 2005;  25(7) 545-546
    CrossrefPubMedGoogle Scholar
  • 91 Fuh J L, Wang S J, Lu S R, Juang K D. Does medication overuse headache represent a behavior of dependence?.  Pain. 2005;  119(1-3) 49-55
    CrossrefPubMedGoogle Scholar
  • 92 Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness.  Cephalalgia. 2006;  26(10) 1192-1198
    CrossrefPubMedGoogle Scholar
  • 93 Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs.  Cephalalgia. 2006;  26(9) 1097-1105
    CrossrefPubMedGoogle Scholar
  • 94 Obermann M, Katsarava Z. Management of medication-overuse headache.  Expert Rev Neurother. 2007;  7(9) 1145-1155
    CrossrefPubMedGoogle Scholar
  • 95 Bøe M G, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.  Neurology. 2007;  69(1) 26-31
    CrossrefPubMedGoogle Scholar
  • 96 Diener H C. How to treat medication-overuse headache: prednisolone or no prednisolone?.  Neurology. 2007;  69(1) 14-15
    CrossrefPubMedGoogle Scholar
  • 97 Mathew N T. Amelioration of ergotamine withdrawal symptoms with naproxen.  Headache. 1987;  27(3) 130-133
    CrossrefPubMedGoogle Scholar
  • 98 Krymchantowski A V, Barbosa J S. Prednisone as initial treatment of analgesic-induced daily headache.  Cephalalgia. 2000;  20(2) 107-113
    CrossrefPubMedGoogle Scholar
  • 99 Lu S R, Fuh J L, Juang K D, Wang S J. Repetitive intravenous prochlorperazine treatment of patients with refractory chronic daily headache.  Headache. 2000;  40(9) 724-729
    CrossrefPubMedGoogle Scholar
  • 100 Silberstein S D, Schulman E A, Hopkins M M. Repetitive intravenous DHE in the treatment of refractory headache.  Headache. 1990;  30(6) 334-339
    CrossrefPubMedGoogle Scholar
  • 101 Ford R G, Ford K T. Continuous intravenous dihydroergotamine in the treatment of intractable headache.  Headache. 1997;  37(3) 129-136
    CrossrefPubMedGoogle Scholar
  • 102 Schwartz T H, Karpitskiy V V, Sohn R S. Intravenous valproate sodium in the treatment of daily headache.  Headache. 2002;  42(6) 519-522
    CrossrefPubMedGoogle Scholar
  • 103 Katsarava Z, Jensen R. Medication-overuse headache: where are we now?.  Curr Opin Neurol. 2007;  20(3) 326-330
    CrossrefPubMedGoogle Scholar
  • 104 Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener H C, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study.  Cephalalgia. 2005;  25(1) 12-15
    CrossrefPubMedGoogle Scholar
  • 105 Garza I, Swanson J W. Answers to frequently asked questions about migraine.  Mayo Clin Proc. 2006;  81(10) 1387-1391, quiz 1392
    CrossrefPubMedGoogle Scholar
  • 106 Rozen T D. New daily persistent headache.  Curr Pain Headache Rep. 2003;  7(3) 218-223
    CrossrefPubMedGoogle Scholar
  • 107 Vanast W J. New daily persistent headaches definition of a benign syndrome.  Headache. 1986;  26 317-320 (Abstract)
    PubMedGoogle Scholar
  • 108 Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan.  Cephalalgia. 2004;  24(11) 955-959
    CrossrefPubMedGoogle Scholar
  • 109 Li D, Rozen T D. The clinical characteristics of new daily persistent headache.  Cephalalgia. 2002;  22(1) 66-69
    CrossrefPubMedGoogle Scholar
  • 110 Bigal M E, Sheftell F D, Rapoport A M, Lipton R B, Tepper S J. Chronic daily headache in a tertiary care population: correlation between the International Headache Society diagnostic criteria and proposed revisions of criteria for chronic daily headache.  Cephalalgia. 2002;  22(6) 432-438
    CrossrefPubMedGoogle Scholar
  • 111 Diaz-Mitoma F, Vanast W J, Tyrrell D L. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches.  Lancet. 1987;  1(8530) 411-415
    CrossrefPubMedGoogle Scholar
  • 112 Hamada T, Ohshima K, Ide Y, Sakato S, Takamori M. A case of new daily persistent headache with elevated antibodies to Epstein-Barr virus.  Jpn J Med. 1991;  30(2) 161-163
    PubMedGoogle Scholar
  • 113 Meineri P, Torre E, Rota E, Grasso E. New daily persistent headache: clinical and serological characteristics in a retrospective study.  Neurol Sci. 2004;  25(Suppl 3) S281-S282
    CrossrefPubMedGoogle Scholar
  • 114 Santoni J R, Santoni-Williams C J. Headache and painful lymphadenopathy in extracranial or systemic infection: etiology of new daily persistent headaches.  Intern Med. 1993;  32(7) 530-532
    CrossrefPubMedGoogle Scholar
  • 115 Rozen T D. New daily persistent headache. In: Goadsby PJ, Dodick DW Chronic Daily Headache for Clinicians. 1st Ed. Hamilton, Ontario; BC Decker Inc. 2005: 209-215
    Google Scholar
  • 116 Goadsby P J, Boes C. New daily persistent headache.  J Neurol Neurosurg Psychiatry. 2002;  72(Suppl 2) ii6-ii9
    PubMedGoogle Scholar
  • 117 Rossi P, Faroni J, Tassorelli C, Nappi G. Diagnostic delay and suboptimal management in a referral population with hemicrania continua.  Headache. 2009;  49(2) 227-234
    CrossrefPubMedGoogle Scholar
  • 118 Peres M F, Silberstein S D, Nahmias S et al.. Hemicrania continua is not that rare.  Neurology. 2001;  57(6) 948-951
    CrossrefPubMedGoogle Scholar
  • 119 Dodick D. Hemicrania continua: diagnostic criteria and nosologic status.  Cephalalgia. 2001;  21(9) 869-872
    CrossrefPubMedGoogle Scholar
  • 120 Matharu M S, Cohen A S, McGonigle D J, Ward N, Frackowiak R S, Goadsby P J. Posterior hypothalamic and brainstem activation in hemicrania continua.  Headache. 2004;  44(8) 747-761
    CrossrefPubMedGoogle Scholar
  • 121 Irimia P, Arbizu J, Prieto E, Fernández-Torrón R, Martínez-Vila E. Activation of the brainstem but not of the hypothalamus in hemicrania continua without autonomic symptoms.  Cephalalgia. 2009;  29(9) 974-979
    CrossrefPubMedGoogle Scholar
  • 122 Matharu M S, Boes C J, Goadsby P J. Management of trigeminal autonomic cephalgias and hemicrania continua.  Drugs. 2003;  63(16) 1637-1677
    CrossrefPubMedGoogle Scholar
  • 123 Marmura M J, Silberstein S D, Gupta M. Hemicrania continua: who responds to indomethacin?.  Cephalalgia. 2009;  29(3) 300-307
    CrossrefPubMedGoogle Scholar
  • 124 Bigal M E, Tepper S J, Rapoport A M, Sheftell F D. Hemicrania continua: comparison between two different classification systems.  Cephalalgia. 2002;  22(3) 242-245
    CrossrefPubMedGoogle Scholar
  • 125 Eross E J, Swanson J W, Dodick D W. Hemicrania continua: an indomethacin-responsive case with an underlying malignant etiology.  Headache. 2002;  42(6) 527-529
    CrossrefPubMedGoogle Scholar
  • 126 Antonaci F, Sjaastad O. Hemicrania continua: a possible symptomatic case, due to mesenchymal tumor.  Funct Neurol. 1992;  7(6) 471-474
    PubMedGoogle Scholar
  • 127 Valença M M, Andrade-Valença L P, da Silva W F, Dodick D W. Hemicrania continua secondary to an ipsilateral brainstem lesion.  Headache. 2007;  47(3) 438-441
    CrossrefPubMedGoogle Scholar
  • 128 Rogalewski A, Evers S. Symptomatic hemicrania continua after internal carotid artery dissection.  Headache. 2005;  45(2) 167-169
    CrossrefPubMedGoogle Scholar
  • 129 Peres M F, Zukerman E, Porto P P, Brandt R A. Headaches and pineal cyst: a (more than) coincidental relationship?.  Headache. 2004;  44(9) 929-930
    CrossrefPubMedGoogle Scholar
  • 130 Levy M J, Matharu M S, Meeran K, Powell M, Goadsby P J. The clinical characteristics of headache in patients with pituitary tumours.  Brain. 2005;  128(Pt 8) 1921-1930
    CrossrefPubMedGoogle Scholar
  • 131 Pareja J, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Interval between indomethacin administration and response.  Headache. 1996;  36(1) 20-23
    CrossrefPubMedGoogle Scholar
  • 132 Pareja J A, Caminero A B, Franco E, Casado J L, Pascual J, Sánchez del Río M. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua.  Cephalalgia. 2001;  21(9) 906-910
    CrossrefPubMedGoogle Scholar
  • 133 Rozen T D. Melatonin responsive hemicrania continua.  Headache. 2006;  46(7) 1203-1204
    CrossrefPubMedGoogle Scholar
  • 134 Peres M F, Silberstein S D. Hemicrania continua responds to cyclooxygenase-2 inhibitors.  Headache. 2002;  42(6) 530-531
    CrossrefPubMedGoogle Scholar
  • 135 Schwedt T J, Dodick D W, Hentz J, Trentman T L, Zimmerman R S. Occipital nerve stimulation for chronic headache—long-term safety and efficacy.  Cephalalgia. 2007;  27(2) 153-157
    CrossrefPubMedGoogle Scholar
  • 136 Camarda C, Camarda R, Monastero R. Chronic paroxysmal hemicrania and hemicrania continua responding to topiramate: two case reports.  Clin Neurol Neurosurg. 2008;  110(1) 88-91
    CrossrefPubMedGoogle Scholar
  • 137 Burns B, Watkins L, Goadsby P J. Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study.  Lancet Neurol. 2008;  7(11) 1001-1012
    CrossrefPubMedGoogle Scholar
  • 138 Garza I, Cutrer F. Pain relief and persistence of dysantonomic features in a patient with hemicrania continua responsive to botulinum toxin type A.  Cephalalgia. 2009;  , June 10 (Epub ahead of print)
    PubMedGoogle Scholar

Ivan GarzaM.D. 

Assistant Professor, Department of Neurology, Mayo Clinic

200 First Street SW, Rochester, MN 55905

Email: garza.ivan@mayo.edu

      >